Dolophine and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
Determining the interaction of Dolophine and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ritonavir together with methadone may decrease the effects of methadone. Contact your doctor if you experience withdrawal symptoms such as restlessness, insomnia, sweating, increased tears, and a runny nose. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Some protease inhibitors have been shown to decrease the plasma concentrations of methadone. In a study of healthy volunteers, peak serum concentration (Cmax) and area under the concentration-time curve (AUC) of methadone decreased by approximately 37% each during coadministration with ritonavir. Similar results have been reported with nelfinavir.
MANAGEMENT: Caution is advised if protease inhibitors are prescribed to patients treated with methadone. Pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of protease inhibitor therapy in patients who are stabilized on their methadone regimen. Patients should be advised to notify their caregiver if they experience possible symptoms of methadone withdrawal such as restlessness, insomnia, sweating, lacrimation, and rhinorrhea.
- Geletko SM, Erickson AD "Decreased methadone effect after ritonavir initiation." Pharmacotherapy 20 (2000): 93-4
- Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D "Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors." AIDS 12 (1998): 2510-1
Generic Name: methadone
Brand name: Dolophine, Methadose, Methadose Sugar-Free, Diskets
Synonyms: n.a.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dolophine-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Dolophine-Omeclamox-Pak
- Dolophine-Omega-3 Fatty Acid Capsules
- Dolophine-Omega-3 Fatty Acids
- Dolophine-Omega-3 polyunsaturated fatty acids
- Dolophine-Omega-3-acid ethyl esters
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Dolor-Parche with Lidocaine
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Dolor-Parche with Lidocaine Patch
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Doloracin Rx
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Doloracin/L Rx with Lidocaine
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Doloracin/L with Lidocaine
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Dolorex